ZNF583 Inhibitors
Chemical inhibitors of ZNF583 act through various mechanisms to impede the pathways and enzymatic activities that are essential for its function. PD98059 and U0126 are both inhibitors of the MEK enzyme, a key component in the MAPK/ERK pathway. By inhibiting MEK, PD98059 and U0126 prevent the phosphorylation and subsequent activation of ERK, which is necessary for downstream signaling that influences the activity of ZNF583. Furthermore, SP600125 and SB203580 target other members of the MAPK family, JNK, and p38 MAP kinase, respectively. SP600125's inhibition of JNK and SB203580's selective inhibition of p38 MAP kinase lead to a decrease in the activity of transcription factors and other regulatory proteins that are involved in the modulation of ZNF583.
Likewise, LY294002 and Wortmannin both function as PI3K inhibitors, obstructing the PI3K/AKT signaling pathway. The inhibition of PI3K leads to a blockade of AKT activation, which in turn affects the activity of transcription factors critical for ZNF583's function. Rapamycin, an mTOR inhibitor, disrupts a downstream component of the PI3K/AKT pathway, leading to reduced activity of proteins that regulate ZNF583. Adding to the complexity of kinase regulation, Y-27632, PP2, and Staurosporine offer distinct inhibitory actions. Y-27632 inhibits ROCK kinase, potentially affecting the localization and function of critical transcription factors for ZNF583. PP2 targets the Src family of kinases, impeding phosphorylation events crucial for ZNF583, while Staurosporine broadly inhibits a range of kinases involved in phosphorylating proteins that interact with ZNF583. Lastly, Alsterpaullone and Bisindolylmaleimide I provide targeted inhibition of CDKs and PKC, respectively, which could result in decreased phosphorylation and activity of proteins involved in the regulation of ZNF583, further showcasing the intricate network of enzymatic control governing the activity of this protein.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits the MEK enzyme, which is part of the MAPK/ERK pathway. ZNF583 activity is dependent on proper transcription factor function which may be regulated by ERK signaling. Inhibition of MEK by PD98059 would prevent the phosphorylation of ERK, thereby inhibiting the downstream signaling required for ZNF583 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. ZNF583 relies on transcription factors that can be activated by PI3K/AKT signaling. Inhibition of PI3K by LY294002 would block AKT activation, which in turn would inhibit the activity of transcription factors crucial for ZNF583 function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1 and MEK2, which are upstream of ERK in the MAPK pathway. By inhibiting MEK1/2, U0126 prevents the activation of ERK, thus inhibiting the signaling that may be necessary for the function of ZNF583. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, which leads to the inhibition of AKT phosphorylation and activation. This inhibitory action disrupts signaling pathways that may be essential for the transcription factors that regulate ZNF583 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK family. JNK signaling can influence transcription factor activity that may be crucial for ZNF583 function. By inhibiting JNK, SP600125 would impede the pathways that contribute to ZNF583 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase, which can regulate transcription factors and other proteins interacting with ZNF583. Inhibition of p38 MAPK by SB203580 would lead to decreased activity of those transcription factors, thereby inhibiting ZNF583 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, and mTOR is a key kinase in the PI3K/AKT pathway. Inhibition of mTOR by rapamycin would lead to reduced protein synthesis and function of proteins involved in the regulation of ZNF583 activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 inhibits ROCK kinase, which can affect cytoskeleton organization and potentially influence the cellular localization and function of transcription factors regulating ZNF583. Inhibition of ROCK by Y-27632 could disrupt cellular processes essential for ZNF583 activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family kinases, which can phosphorylate substrates that interact with ZNF583. Inhibition of these kinases by PP2 would impede phosphorylation events necessary for ZNF583 activity. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a CDK inhibitor, which could affect the cell cycle and hinder the function of transcription factors or other regulatory proteins that are essential for ZNF583 activity. By inhibiting CDKs, Alsterpaullone would prevent the phosphorylation and activity of proteins involved with ZNF583. | ||||||